EGFR-targeted adenovirus dendrimer coating for improved systemic delivery of the theranostic NIS gene

Molecular Therapy Nucleic Acids

Volumn 2, Issue NOV, 2013, Pages e131-

  Grünwald, Geoffrey K ^a   Vetter, Alexandra ^b   Klutz, Kathrin ^a   Willhauck, Michael J ^a   Schwenk, Nathalie ^a   Senekowitsch Schmidtke, Reingard ^c   Schwaiger, Markus ^c   Zach, Christian ^a   Wagner, Ernst ^b   Göke, Burkhard ^a   Holm, Per S ^c   Ogris, Manfred ^b   Spitzweg, Christine ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ALANINE AMINOTRANSFERASE; ALPHA FETOPROTEIN; ASPARTATE AMINOTRANSFERASE; CETUXIMAB; COXSACKIE VIRUS AND ADENOVIRUS RECEPTOR; DENDRIMER; EPIDERMAL GROWTH FACTOR RECEPTOR; IODINE 123; POLYAMIDOAMINE; RADIOACTIVE IODINE; SODIUM IODIDE SYMPORTER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER RADIOTHERAPY; CELL VIABILITY; CONJUGATE; CONTROLLED STUDY; GENE EXPRESSION; GENE TARGETING; GENE TRANSFER; HEPG2 CELL LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER CELL CARCINOMA; LIVER TOXICITY; MOUSE; NONHUMAN; ONCOLYTIC VIROTHERAPY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIOVIROTHERAPY; SINGLE DRUG DOSE; TUMOR GROWTH; TUMOR VOLUME; TUMOR XENOGRAFT; VIRAL TROPISM;

EID: 84903759709     PISSN: None     EISSN: 21622531     Source Type: Journal    
DOI: 10.1038/mtna.2013.58     Document Type: Article

References (46)

1. Grünwald, GK, Vetter, A, Klutz, K, Willhauck, MJ, Schwenk, N, Senekowitsch-Schmidtke, R et al. (2013). Systemic image-guided liver cancer radiovirotherapy using dendrimer-coated adenovirus encoding the sodium iodide symporter as theranostic gene. J Nucl Med 54: 1450-1457.
2. Vetter, A, Virdi, KS, Espenlaub, S, Rödl, W, Wagner, E, Holm, PS et al. (2013). Adenoviral vectors coated with PAMAM dendrimer conjugates allow CAR independent virus uptake and targeting to the EGF receptor. Mol Pharm 10: 606-618.
3. Choi, JW, Lee, JS, Kim, SW and Yun, CO (2012). Evolution of oncolytic adenovirus for cancer treatment. Adv Drug Deliv Rev 64: 720-729.
4. Kim, PH, Sohn, JH, Choi, JW, Jung, Y, Kim, SW, Haam, S et al. (2011). Active targeting and safety profile of PEG-modified adenovirus conjugated with herceptin. Biomaterials 32: 2314-2326.
5. Campos, SK and Barry, MA (2007). Current advances and future challenges in Adenoviral vector biology and targeting. Curr Gene Ther 7: 189-204. (Pubitemid 46902201)
6. Duffy, MR, Parker, AL, Bradshaw, AC and Baker, AH (2012). Manipulation of adenovirus interactions with host factors for gene therapy applications. Nanomedicine (Lond) 7: 271-288.
7. Rojas, JJ, Gimenez-Alejandre, M, Gil-Hoyos, R, Cascallo, M and Alemany, R (2012). Improved systemic antitumor therapy with oncolytic adenoviruses by replacing the fiber shaft HSG-binding domain with RGD. Gene Ther 19: 453-457.
8. Yao, X, Yoshioka, Y, Morishige, T, Eto, Y, Narimatsu, S, Kawai, Y et al. (2011). Tumor vascular targeted delivery of polymer-conjugated adenovirus vector for cancer gene therapy. Mol Ther 19: 1619-1625.
9. Yao, XL, Nakagawa, S and Gao, JQ (2011). Current targeting strategies for adenovirus vectors in cancer gene therapy. Curr Cancer Drug Targets 11: 810-825.
10. Harari, PM (2004). Epidermal growth factor receptor inhibition strategies in oncology. Endocr Relat Cancer 11: 689-708.
11. de Bruin, K, Ruthardt, N, von Gersdorff, K, Bausinger, R, Wagner, E, Ogris, M et al. (2007). Cellular dynamics of EGF receptor-targeted synthetic viruses. Mol Ther 15: 1297-1305. (Pubitemid 46965326)
12. Harvey, TJ, Burdon, D, Steele, L, Ingram, N, Hall, GD, Selby, PJ et al. (2010). Retargeted adenoviral cancer gene therapy for tumour cells overexpressing epidermal growth factor receptor or urokinase-type plasminogen activator receptor. Gene Ther 17: 1000-1010.
13. Kawashima, R, Abei, M, Fukuda, K, Nakamura, K, Murata, T, Wakayama, M et al. (2011). EpCAM- and EGFR-targeted selective gene therapy for biliary cancers using Z33-fiber-modified adenovirus. Int J Cancer 129: 1244-1253.
14. Klutz, K, Schaffert, D, Willhauck, MJ, Grünwald, GK, Haase, R, Wunderlich, N et al. (2011). Epidermal growth factor receptor-targeted (131)I-therapy of liver cancer following systemic delivery of the sodium iodide symporter gene. Mol Ther 19: 676-685.
15. Li, Z, Zhao, R, Wu, X, Sun, Y, Yao, M, Li, J et al. (2005). Identification and characterization of a novel peptide ligand of epidermal growth factor receptor for targeted delivery of therapeutics. FASEB J 19: 1978-1985. (Pubitemid 41759743)
16. Spitzweg, C and Morris, JC (2002). The sodium iodide symporter: its pathophysiological and therapeutic implications. Clin Endocrinol (Oxf) 57: 559-574. (Pubitemid 35316971)
17. Hingorani, M, Spitzweg, C, Vassaux, G, Newbold, K, Melcher, A, Pandha, H et al. (2010). The biology of the sodium iodide symporter and its potential for targeted gene delivery. Curr Cancer Drug Targets 10: 242-267.
18. Spitzweg, C and Morris, JC (2004). Gene therapy for thyroid cancer: current status and future prospects. Thyroid 14: 424-434. (Pubitemid 38868761)
19. Maeda, H (2001). The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv Enzyme Regul 41: 189-207.
20. Kalyuzhniy, O, Di Paolo, NC, Silvestry, M, Hofherr, SE, Barry, MA, Stewart, PL et al. (2008). Adenovirus serotype 5 hexon is critical for virus infection of hepatocytes in vivo. Proc Natl Acad Sci USA 105: 5483-5488. (Pubitemid 351753889)
21. Vigant, F, Descamps, D, Jullienne, B, Esselin, S, Connault, E, Opolon, P et al. (2008). Substitution of hexon hypervariable region 5 of adenovirus serotype 5 abrogates blood factor binding and limits gene transfer to liver. Mol Ther 16: 1474-1480.
22. Waddington, SN, McVey, JH, Bhella, D, Parker, AL, Barker, K, Atoda, H et al. (2008). Adenovirus serotype 5 hexon mediates liver gene transfer. Cell 132: 397-409. (Pubitemid 351200513)
23. Huard, J, Lochmüller, H, Acsadi, G, Jani, A, Massie, B and Karpati, G (1995). The route of administration is a major determinant of the transduction efficiency of rat tissues by adenoviral recombinants. Gene Ther 2: 107-115.
24. Green, NK, Morrison, J, Hale, S, Briggs, SS, Stevenson, M, Subr, V et al. (2008). Retargeting polymer-coated adenovirus to the FGF receptor allows productive infection and mediates efficacy in a peritoneal model of human ovarian cancer. J Gene Med 10: 280-289. (Pubitemid 351359640)
25. Kanerva, A and Hemminki, A (2005). Adenoviruses for treatment of cancer. Ann Med 37: 33-43. (Pubitemid 40342423)
26. Cattaneo, R, Miest, T, Shashkova, EV and Barry, MA (2008). Reprogrammed viruses as cancer therapeutics: targeted, armed and shielded. Nat Rev Microbiol 6: 529-540. (Pubitemid 351850977)
27. Kim, J, Kim, PH, Kim, SW and Yun, CO (2012). Enhancing the therapeutic efficacy of adenovirus in combination with biomaterials. Biomaterials 33: 1838-1850.
28. Mizuguchi, H and Hayakawa, T (2004). Targeted adenovirus vectors. Hum Gene Ther 15: 1034-1044. (Pubitemid 39552285)
29. Grünwald, GK, Klutz, K, Willhauck, MJ, Schwenk, N, Senekowitsch-Schmidtke, R, Schwaiger, M et al. (2013). Sodium iodide symporter (NIS)-mediated radiovirotherapy of hepatocellular cancer using a conditionally replicating adenovirus. Gene Ther 20: 625-633.
30. Iyer, AK, Khaled, G, Fang, J and Maeda, H (2006). Exploiting the enhanced permeability and retention effect for tumor targeting. Drug Discov Today 11: 812-818. (Pubitemid 44280021)
31. Fechner, H, Haack, A, Wang, H, Wang, X, Eizema, K, Pauschinger, M et al. (1999). Expression of coxsackie adenovirus receptor and alphav-integrin does not correlate with adenovector targeting in vivo indicating anatomical vector barriers. Gene Ther 6: 1520-1535. (Pubitemid 29465510)
32. Tallone, T, Malin, S, Samuelsson, A, Wilbertz, J, Miyahara, M, Okamoto, K et al. (2001). A mouse model for adenovirus gene delivery. Proc Natl Acad Sci USA 98: 7910-7915. (Pubitemid 32642661)
33. Tomko, RP, Xu, R and Philipson, L (1997). HCAR and MCAR: the human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackieviruses. Proc Natl Acad Sci USA 94: 3352-3356. (Pubitemid 27157315)
34. Blair, GE, Dixon, SC, Griffiths, SA and Zajdel, ME (1989). Restricted replication of human adenovirus type 5 in mouse cell lines. Virus Res 14: 339-346. (Pubitemid 20014461)
35. Jauregui-Osoro, M, Sunassee, K, Weeks, AJ, Berry, DJ, Paul, RL, Cleij, M et al. (2010). Synthesis and biological evaluation of [(18)F]tetrafluoroborate: a PET imaging agent for thyroid disease and reporter gene imaging of the sodium/iodide symporter. Eur J Nucl Med Mol Imaging 37: 2108-2116.
36. Weeks, AJ, Jauregui-Osoro, M, Cleij, M, Blower, JE, Ballinger, JR and Blower, PJ (2011). Evaluation of [18F]-tetrafluoroborate as a potential PET imaging agent for the human sodium/iodide symporter in a new colon carcinoma cell line, HCT116, expressing hNIS. Nucl Med Commun 32: 98-105.
37. Xu, Z, Tian, J, Smith, JS and Byrnes, AP (2008). Clearance of adenovirus by Kupffer cells is mediated by scavenger receptors, natural antibodies, and complement. J Virol 82: 11705-11713.
38. Advani, SJ, Mezhir, JJ, Roizman, B and Weichselbaum, RR (2006). ReVOLT: radiation-enhanced viral oncolytic therapy. Int J Radiat Oncol Biol Phys 66: 637-646. (Pubitemid 44436713)
39. Dilley, J, Reddy, S, Ko, D, Nguyen, N, Rojas, G, Working, P et al. (2005). Oncolytic adenovirus CG7870 in combination with radiation demonstrates synergistic enhancements of antitumor efficacy without loss of specificity. Cancer Gene Ther 12: 715-722. (Pubitemid 41045570)
40. Trujillo, MA, Oneal, MJ, McDonough, SJ and Morris, JC (2013). Viral dose, radioiodide uptake, and delayed efflux in adenovirus-mediated NIS radiovirotherapy correlates with treatment efficacy. Gene Ther 20: 567-574.
41. Lamfers, ML, Grill, J, Dirven, CM, Van Beusechem, VW, Geoerger, B, Van Den Berg, J et al. (2002). Potential of the conditionally replicative adenovirus Ad5-Delta24RGD in the treatment of malignant gliomas and its enhanced effect with radiotherapy. Cancer Res 62: 5736-5742. (Pubitemid 35204729)
42. Trujillo, MA, Oneal, MJ, McDonough, S, Qin, R and Morris, JC (2012). A steep radioiodine dose response scalable to humans in sodium-iodide symporter (NIS)-mediated radiovirotherapy for prostate cancer. Cancer Gene Ther 19: 839-844.
43. U.S. National Institute of Health (2012). Gene Therapy and Radioactive Iodine in Treating Patients With Locally Recurrent Prostate Cancer That Did Not Respond to External-Beam Radiation Therapy 〈http://clinicaltrials.gov/ct/ show/NCT00788307〉.
44. Spitzweg, C, Dietz, AB, O'Connor, MK, Bergert, ER, Tindall, DJ, Young, CY et al. (2001). In vivo sodium iodide symporter gene therapy of prostate cancer. Gene Ther 8: 1524-1531. (Pubitemid 33061890)
45. Klutz, K, Willhauck, MJ, Wunderlich, N, Zach, C, Anton, M, Senekowitsch-Schmidtke, R et al. (2011). Sodium iodide symporter (NIS)-mediated radionuclide ((131)I, (188)Re) therapy of liver cancer after transcriptionally targeted intratumoral in vivo NIS gene delivery. Hum Gene Ther 22: 1403-1412.
46. Willhauck, MJ, Sharif Samani, BR, Gildehaus, FJ, Wolf, I, Senekowitsch-Schmidtke, R, Stark, HJ et al. (2007). Application of 188rhenium as an alternative radionuclide for treatment of prostate cancer after tumor-specific sodium iodide symporter gene expression. J Clin Endocrinol Metab 92: 4451-4458. (Pubitemid 350074769)